Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

Condition(s) studied

Investigational drug(s) / intervention(s)

DUPIXENT®: No investigational agents will be provided. All treatments will be prescribed at the discretion of the study physician and other healthcare providers.

Study summary

The primary objectives of the study are:

* To longitudinally characterize the long-term effectiveness of DUPIXENT® through assessment of patient-reported symptoms, Health-Related Quality of Life (HRQoL) related to Chronic rhinosinusitis with nasal polyposis (CRSwNP) and other type 2 comorbidities, and their change over-time.
* To characterize patients who receive DUPIXENT® for CRSwNP in a real-world setting with respect to their medical history, demographic and disease characteristics, and type 2 comorbidities

The secondary objectives of the study are:

* To characterize real-world utilization of DUPIXENT® for patients with CRSwNP
* To collect patient and physician global assessment of disease severity and treatment satisfaction for patients receiving DUPIXENT® for CRSwNP
* To collect long-term safety data for patients receiving DUPIXENT® for CRSwNP

Eligibility

Primary outcome measure(s)

• Baseline Patient Characteristics — Baseline up to 3 years
  Demographics includes but is not limited to gender, age, ethnicity, height, weight, BMI, education, current employment status, physician information.
• Baseline Disease Characteristics — Baseline up to 3 years
  Medical History includes but is not limited to history of CRSwNP, comorbid conditions, age at CRSwNP diagnosis, and baseline measurements of effectiveness variables.

Trial sites (81)

+ 41 more sites — see the full list on the official registry below.

More Regeneron Pharmaceuticals trials in the USA